 Joseph Kay
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Defects, Congenital | 23 | 2024 | 792 | 1.900 |
Why?
| | Transposition of Great Vessels | 8 | 2024 | 36 | 1.370 |
Why?
| | Tetralogy of Fallot | 9 | 2018 | 78 | 0.930 |
Why?
| | Fontan Procedure | 6 | 2024 | 174 | 0.910 |
Why?
| | Cardiac Catheterization | 9 | 2024 | 520 | 0.780 |
Why?
| | Aortic Coarctation | 3 | 2023 | 81 | 0.640 |
Why?
| | Catheter Ablation | 8 | 2019 | 336 | 0.580 |
Why?
| | Stents | 6 | 2018 | 504 | 0.560 |
Why?
| | Atrial Fibrillation | 6 | 2022 | 376 | 0.560 |
Why?
| | Tachycardia, Ventricular | 5 | 2019 | 168 | 0.520 |
Why?
| | Pacemaker, Artificial | 3 | 2020 | 110 | 0.520 |
Why?
| | Hypoplastic Left Heart Syndrome | 3 | 2024 | 121 | 0.510 |
Why?
| | Cardiology | 2 | 2020 | 266 | 0.500 |
Why?
| | Pulmonary Valve | 5 | 2018 | 93 | 0.480 |
Why?
| | Thromboembolism | 4 | 2024 | 112 | 0.410 |
Why?
| | Heart Failure | 5 | 2025 | 2133 | 0.400 |
Why?
| | Heart Valve Diseases | 3 | 2020 | 152 | 0.390 |
Why?
| | Heart Septal Defects, Atrial | 3 | 2013 | 54 | 0.390 |
Why?
| | Ultrasonography, Interventional | 3 | 2013 | 128 | 0.350 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2023 | 231 | 0.340 |
Why?
| | Arrhythmias, Cardiac | 5 | 2024 | 320 | 0.340 |
Why?
| | Coronary Angiography | 5 | 2024 | 306 | 0.340 |
Why?
| | Heart Ventricles | 4 | 2024 | 781 | 0.330 |
Why?
| | Heart Valve Prosthesis Implantation | 4 | 2018 | 177 | 0.330 |
Why?
| | Arterial Switch Operation | 2 | 2022 | 9 | 0.330 |
Why?
| | Adult | 44 | 2024 | 35599 | 0.320 |
Why?
| | Sick Sinus Syndrome | 1 | 2009 | 2 | 0.310 |
Why?
| | Electrophysiologic Techniques, Cardiac | 7 | 2019 | 79 | 0.310 |
Why?
| | Treatment Outcome | 22 | 2024 | 10219 | 0.300 |
Why?
| | Bradycardia | 1 | 2009 | 53 | 0.300 |
Why?
| | Antiphospholipid Syndrome | 1 | 2009 | 37 | 0.300 |
Why?
| | Catheterization | 2 | 2010 | 175 | 0.300 |
Why?
| | Follow-Up Studies | 14 | 2024 | 4894 | 0.290 |
Why?
| | Aneurysm, False | 1 | 2008 | 47 | 0.290 |
Why?
| | Atrial Flutter | 3 | 2017 | 35 | 0.260 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2008 | 127 | 0.260 |
Why?
| | Male | 45 | 2024 | 63670 | 0.260 |
Why?
| | Retrospective Studies | 24 | 2024 | 14522 | 0.250 |
Why?
| | Humans | 64 | 2025 | 129626 | 0.250 |
Why?
| | Hemodynamics | 4 | 2025 | 1090 | 0.240 |
Why?
| | Hypertension | 3 | 2023 | 1243 | 0.240 |
Why?
| | Female | 43 | 2024 | 68734 | 0.240 |
Why?
| | Cardiac Surgical Procedures | 4 | 2018 | 506 | 0.240 |
Why?
| | Forecasting | 2 | 2017 | 361 | 0.240 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 3 | 2016 | 30 | 0.230 |
Why?
| | Cardiac Output | 1 | 2025 | 156 | 0.230 |
Why?
| | Cryosurgery | 2 | 2018 | 57 | 0.220 |
Why?
| | Pulmonary Valve Insufficiency | 3 | 2016 | 40 | 0.220 |
Why?
| | Vascular Fistula | 1 | 2024 | 22 | 0.220 |
Why?
| | Heart Rate | 3 | 2019 | 802 | 0.210 |
Why?
| | Risk Assessment | 5 | 2017 | 3262 | 0.210 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2023 | 24 | 0.210 |
Why?
| | Echocardiography, Transesophageal | 3 | 2010 | 92 | 0.210 |
Why?
| | Heart Transplantation | 3 | 2024 | 721 | 0.210 |
Why?
| | Electrocardiography | 7 | 2017 | 611 | 0.210 |
Why?
| | Prostheses and Implants | 1 | 2004 | 135 | 0.200 |
Why?
| | Postoperative Complications | 4 | 2024 | 2477 | 0.190 |
Why?
| | Takayasu Arteritis | 1 | 2001 | 15 | 0.190 |
Why?
| | Young Adult | 17 | 2024 | 12455 | 0.180 |
Why?
| | Anticoagulants | 3 | 2022 | 637 | 0.180 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1021 | 0.180 |
Why?
| | American Heart Association | 3 | 2017 | 300 | 0.180 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2023 | 272 | 0.180 |
Why?
| | Continuity of Patient Care | 3 | 2020 | 273 | 0.180 |
Why?
| | Adolescent | 17 | 2024 | 20412 | 0.180 |
Why?
| | Heart Septal Defects, Ventricular | 2 | 2019 | 41 | 0.180 |
Why?
| | Time Factors | 8 | 2024 | 6555 | 0.170 |
Why?
| | Data Collection | 2 | 2013 | 650 | 0.170 |
Why?
| | Middle Aged | 21 | 2024 | 31136 | 0.170 |
Why?
| | Radiology, Interventional | 1 | 2020 | 30 | 0.170 |
Why?
| | Cardiologists | 1 | 2020 | 46 | 0.170 |
Why?
| | Child Welfare | 1 | 2001 | 210 | 0.160 |
Why?
| | Prevalence | 8 | 2024 | 2564 | 0.160 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2013 | 385 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2023 | 639 | 0.150 |
Why?
| | Marfan Syndrome | 2 | 2019 | 39 | 0.150 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2018 | 40 | 0.150 |
Why?
| | Exercise | 2 | 2025 | 1928 | 0.150 |
Why?
| | Patient Education as Topic | 2 | 2013 | 737 | 0.150 |
Why?
| | Aortic Valve Insufficiency | 2 | 2015 | 46 | 0.150 |
Why?
| | Preoperative Care | 2 | 2018 | 338 | 0.140 |
Why?
| | Child, Preschool | 10 | 2024 | 10490 | 0.140 |
Why?
| | Antihypertensive Agents | 1 | 2001 | 485 | 0.140 |
Why?
| | Coronary Artery Disease | 1 | 2024 | 679 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 179 | 0.140 |
Why?
| | Tachycardia, Reciprocating | 1 | 2017 | 6 | 0.140 |
Why?
| | Aortic Valve Stenosis | 1 | 2020 | 218 | 0.140 |
Why?
| | Heart Valve Prosthesis | 1 | 2018 | 112 | 0.140 |
Why?
| | Tachycardia, Supraventricular | 1 | 2017 | 44 | 0.140 |
Why?
| | Hepatic Veins | 2 | 2016 | 31 | 0.130 |
Why?
| | Pediatrics | 2 | 2001 | 1056 | 0.130 |
Why?
| | Aortic Valve | 2 | 2020 | 347 | 0.130 |
Why?
| | Survivors | 1 | 2020 | 460 | 0.130 |
Why?
| | Child | 14 | 2024 | 20884 | 0.130 |
Why?
| | Aorta | 2 | 2023 | 408 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2023 | 833 | 0.130 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 811 | 0.130 |
Why?
| | Tachycardia | 1 | 2016 | 57 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 442 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 287 | 0.120 |
Why?
| | Age Factors | 6 | 2017 | 3152 | 0.120 |
Why?
| | Biomedical Research | 2 | 2013 | 640 | 0.120 |
Why?
| | Vectorcardiography | 1 | 2014 | 5 | 0.120 |
Why?
| | Pulmonary Veins | 1 | 2016 | 98 | 0.120 |
Why?
| | Radiography, Interventional | 2 | 2013 | 105 | 0.110 |
Why?
| | Tricuspid Valve | 1 | 2014 | 27 | 0.110 |
Why?
| | Glutamate Carboxypeptidase II | 1 | 2013 | 5 | 0.110 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2013 | 11 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 4 | 2015 | 2512 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 537 | 0.110 |
Why?
| | Disease Management | 1 | 2017 | 588 | 0.110 |
Why?
| | Antigens, Surface | 1 | 2013 | 152 | 0.110 |
Why?
| | Eisenmenger Complex | 1 | 2013 | 11 | 0.100 |
Why?
| | Cardiac Care Facilities | 1 | 2013 | 12 | 0.100 |
Why?
| | Electrodes, Implanted | 1 | 2013 | 106 | 0.100 |
Why?
| | Heart Atria | 1 | 2014 | 129 | 0.100 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 198 | 0.100 |
Why?
| | Portal Vein | 1 | 2014 | 108 | 0.100 |
Why?
| | Microbubbles | 1 | 2013 | 48 | 0.100 |
Why?
| | Diastole | 1 | 2013 | 148 | 0.100 |
Why?
| | Hypoxia | 1 | 2020 | 1084 | 0.100 |
Why?
| | Prosthesis Design | 3 | 2018 | 309 | 0.100 |
Why?
| | Sodium Chloride | 1 | 2013 | 137 | 0.100 |
Why?
| | Risk Factors | 8 | 2024 | 9786 | 0.100 |
Why?
| | Predictive Value of Tests | 6 | 2014 | 1947 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2019 | 2739 | 0.090 |
Why?
| | Aortic Diseases | 1 | 2012 | 113 | 0.090 |
Why?
| | Therapy, Computer-Assisted | 1 | 2011 | 60 | 0.090 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 99 | 0.090 |
Why?
| | Mental Disorders | 1 | 2019 | 1034 | 0.090 |
Why?
| | Angioplasty, Balloon | 1 | 2011 | 92 | 0.090 |
Why?
| | Exercise Test | 3 | 2023 | 613 | 0.090 |
Why?
| | Heart Diseases | 3 | 2013 | 352 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 2 | 2011 | 528 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 78 | 0.090 |
Why?
| | Internship and Residency | 1 | 2020 | 1050 | 0.080 |
Why?
| | Echocardiography | 1 | 2013 | 634 | 0.080 |
Why?
| | Prospective Studies | 7 | 2018 | 7135 | 0.080 |
Why?
| | Patient Participation | 1 | 2013 | 414 | 0.080 |
Why?
| | Infant | 6 | 2024 | 8995 | 0.080 |
Why?
| | Cell Movement | 1 | 2013 | 948 | 0.080 |
Why?
| | Clinical Trials as Topic | 3 | 2003 | 1005 | 0.080 |
Why?
| | Anti-Arrhythmia Agents | 2 | 2019 | 112 | 0.070 |
Why?
| | Equipment Failure | 1 | 2009 | 106 | 0.070 |
Why?
| | Cost of Illness | 2 | 2024 | 277 | 0.070 |
Why?
| | Chest Pain | 1 | 2009 | 88 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 2011 | 391 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1336 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2001 | 1432 | 0.070 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 286 | 0.070 |
Why?
| | Cross-Sectional Studies | 6 | 2013 | 5075 | 0.070 |
Why?
| | Fosinopril | 1 | 2006 | 1 | 0.070 |
Why?
| | Oxygen Consumption | 2 | 2025 | 672 | 0.060 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 203 | 0.060 |
Why?
| | Aged | 7 | 2020 | 22061 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1097 | 0.060 |
Why?
| | Physicians | 1 | 2013 | 866 | 0.060 |
Why?
| | United States | 6 | 2018 | 13871 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2013 | 1280 | 0.060 |
Why?
| | Incidence | 2 | 2024 | 2641 | 0.060 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2024 | 66 | 0.060 |
Why?
| | Altitude | 1 | 2008 | 462 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 712 | 0.050 |
Why?
| | North America | 1 | 2024 | 292 | 0.050 |
Why?
| | Patient Selection | 2 | 2010 | 661 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2019 | 7052 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2025 | 273 | 0.050 |
Why?
| | International Normalized Ratio | 1 | 2022 | 46 | 0.050 |
Why?
| | Vitamin K | 1 | 2022 | 41 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2024 | 276 | 0.050 |
Why?
| | Digoxin | 1 | 2001 | 28 | 0.050 |
Why?
| | Prognosis | 2 | 2024 | 3774 | 0.050 |
Why?
| | Carotid Artery Diseases | 1 | 2002 | 64 | 0.050 |
Why?
| | Pulmonary Atresia | 2 | 2012 | 20 | 0.050 |
Why?
| | Diuretics | 1 | 2001 | 77 | 0.050 |
Why?
| | Ethics, Medical | 1 | 2001 | 78 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2001 | 76 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 5426 | 0.040 |
Why?
| | Arteries | 1 | 2022 | 265 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1499 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2007 | 903 | 0.040 |
Why?
| | Social Support | 1 | 2024 | 584 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 262 | 0.040 |
Why?
| | Reference Values | 1 | 2001 | 794 | 0.040 |
Why?
| | Gonadal Dysgenesis | 1 | 2019 | 8 | 0.040 |
Why?
| | Ultrasonography | 2 | 2014 | 712 | 0.040 |
Why?
| | Philadelphia | 1 | 2019 | 47 | 0.040 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 321 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2014 | 1843 | 0.040 |
Why?
| | Coronary Disease | 1 | 2002 | 385 | 0.040 |
Why?
| | Prader-Willi Syndrome | 1 | 2019 | 27 | 0.040 |
Why?
| | DiGeorge Syndrome | 1 | 2019 | 29 | 0.040 |
Why?
| | Colorado | 2 | 2019 | 4404 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2455 | 0.040 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2019 | 61 | 0.040 |
Why?
| | Quality of Life | 2 | 2024 | 2688 | 0.040 |
Why?
| | Fragile X Syndrome | 1 | 2019 | 81 | 0.040 |
Why?
| | Mood Disorders | 1 | 2019 | 121 | 0.040 |
Why?
| | Palliative Care | 1 | 2024 | 702 | 0.040 |
Why?
| | Hemorrhage | 1 | 2022 | 680 | 0.040 |
Why?
| | Quebec | 1 | 2017 | 10 | 0.040 |
Why?
| | Perioperative Period | 1 | 2017 | 49 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 618 | 0.030 |
Why?
| | Heart Conduction System | 1 | 2017 | 95 | 0.030 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2017 | 58 | 0.030 |
Why?
| | Reoperation | 1 | 2019 | 541 | 0.030 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2020 | 286 | 0.030 |
Why?
| | Blood Pressure | 1 | 2023 | 1736 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1365 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1011 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2019 | 353 | 0.030 |
Why?
| | Action Potentials | 1 | 2019 | 485 | 0.030 |
Why?
| | Electric Stimulation | 1 | 2016 | 267 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2008 | 5756 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 503 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 126 | 0.030 |
Why?
| | Angiography | 1 | 2015 | 196 | 0.030 |
Why?
| | Liver Diseases | 1 | 2017 | 290 | 0.030 |
Why?
| | Recovery of Function | 1 | 2018 | 642 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2016 | 234 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1019 | 0.030 |
Why?
| | Health Surveys | 1 | 2016 | 493 | 0.030 |
Why?
| | Kidney Diseases | 1 | 2017 | 383 | 0.030 |
Why?
| | Curriculum | 1 | 2020 | 920 | 0.030 |
Why?
| | Prostatectomy | 1 | 2013 | 103 | 0.030 |
Why?
| | Phlebography | 1 | 2013 | 37 | 0.030 |
Why?
| | Sinus of Valsalva | 1 | 2012 | 10 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2012 | 60 | 0.030 |
Why?
| | Surgery, Computer-Assisted | 1 | 2013 | 77 | 0.030 |
Why?
| | Clinical Competence | 1 | 2020 | 1017 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2013 | 282 | 0.030 |
Why?
| | Down Syndrome | 1 | 2019 | 478 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 307 | 0.020 |
Why?
| | Prosthesis Implantation | 1 | 2013 | 146 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2013 | 216 | 0.020 |
Why?
| | Fluoroscopy | 1 | 2013 | 157 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2013 | 108 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 1986 | 0.020 |
Why?
| | RNA Interference | 1 | 2013 | 450 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 949 | 0.020 |
Why?
| | Cineangiography | 1 | 2011 | 9 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 851 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 611 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1206 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 234 | 0.020 |
Why?
| | Substance-Related Disorders | 1 | 2019 | 1020 | 0.020 |
Why?
| | Septal Occluder Device | 1 | 2010 | 30 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 869 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1282 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1685 | 0.020 |
Why?
| | Tricuspid Atresia | 1 | 2008 | 5 | 0.020 |
Why?
| | Venae Cavae | 1 | 2008 | 8 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 393 | 0.020 |
Why?
| | Vena Cava, Superior | 1 | 2008 | 22 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 149 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1592 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 819 | 0.020 |
Why?
| | Treatment Failure | 1 | 2008 | 339 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1164 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1687 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2008 | 431 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3186 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 998 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3080 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2720 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2007 | 263 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 740 | 0.010 |
Why?
| | Length of Stay | 1 | 2008 | 1122 | 0.010 |
Why?
| | Animals | 1 | 2025 | 35391 | 0.010 |
Why?
| | ortho-Aminobenzoates | 1 | 2002 | 8 | 0.010 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 22 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3394 | 0.010 |
Why?
| | Coronary Restenosis | 1 | 2002 | 21 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2011 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 1875 | 0.010 |
Why?
| | Paclitaxel | 1 | 2002 | 217 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5415 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 333 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6417 | 0.010 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2002 | 443 | 0.010 |
Why?
| | Body Mass Index | 1 | 2006 | 2274 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2002 | 2046 | 0.010 |
Why?
|
|
Kay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|